SCHEMBL8254136

SCHEMBL8254136

Cc1ccc(Nc2cc(N(C)C)nc(N3CCN(c4ccc(Cl)cc4)CC3)n2)cc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYBB P04839 3/20 0.51
NOX4 Q9NPH5 3/20 0.51
NOX5 Q96PH1 2/20 0.51
NOX3 Q9HBY0 2/20 0.51
NOX1 Q9Y5S8 2/20 0.51
MAPT P10636 5/20 0.49
POLB P06746 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
LMNA P02545 2/20 0.43
TDP1 Q9NUW8 3/20 0.43
MAPK1 P28482 3/20 0.42
BRD4 O60885 1/20 0.41
SCN9A Q15858 1/20 0.40
GALR2 O43603 1/20 0.39
GALR1 P47211 1/20 0.39
HPGD P15428 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ROCK2 O75116 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8253256 0.89 LMNA (0.52) CYBBNOX4NOX5NOX3NOX1
SCHEMBL8256719 0.89 LMNA (0.48) CYBBNOX4NOX5NOX3NOX1
SCHEMBL8254234 0.88 MAPT (0.47) MAPTPOLBNPSR1LMNATDP1
SCHEMBL8256912 0.85 EGFR (0.43) MAPTPOLBNPSR1LMNATDP1
SCHEMBL8254467 0.84 MAPT (0.48) CYBBNOX4NOX5NOX3NOX1
SCHEMBL8253262 0.84 MAPT (0.44) CYBBNOX4MAPTPOLBNPSR1
SCHEMBL3246394 0.83 MAPT (0.57) CYBBNOX4NOX5NOX3NOX1
SCHEMBL8256924 0.82 GALR2 (0.56) MAPTLMNATDP1MAPK1BRD4
SCHEMBL8247655 0.81 GALR2 (0.40) MAPTPOLBNPSR1LMNATDP1
SCHEMBL8254470 0.79 GALR2 (0.42) CYBBNOX4NOX5NOX3NOX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety GALR3, GALR2, GALR1 CYBB 3197/4885NOX4 2295/4885NOX5 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.